Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/9/2022 | $17.00 → $12.00 | Overweight | Piper Sandler |
| 12/3/2021 | $17.00 → $12.00 | Outperform | SVB Leerink |
| 11/16/2021 | $17.00 | Outperform | SVB Leerink |
| 11/16/2021 | $15.00 | Buy | UBS |
| 11/16/2021 | $14.00 | Overweight | JP Morgan |
| 11/16/2021 | $17.00 | Overweight | Piper Sandler |
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o
SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co
SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe
SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o
SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co
15-12G - MINERVA SURGICAL INC (0001452965) (Filer)
25 - MINERVA SURGICAL INC (0001452965) (Filer)
S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)
Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously
SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously
SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
4 - MINERVA SURGICAL INC (0001452965) (Issuer)
3 - MINERVA SURGICAL INC (0001452965) (Issuer)
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro
SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an
SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo
Gainers Biomerica (NASDAQ:BMRA) shares rose 54.5% to $1.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $25.7 million. Cingulate (NASDAQ:CING) stock increased by 33.33% to $2.84. The company's market cap stands at $2.6 million. Arcutis Biotherapeutics (NASDAQ:ARQT) stock increased by 31.14% to $3.2. The market value of their outstanding shares is at $302.0 million. Panbela Therapeutics (NASDAQ:PBLA) shares increased by 30.54% to $0.6. The market value of their outstanding shares is at $3.0 million. NRX Pharmaceuticals (NASDAQ:NRXP) shares rose 30.08% to $0.44. The company's market cap stands at $37.5 million. Alaunos Therapeutics (NASDAQ:TCRT)
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer. Lantheus Holdings shares dipped 22.5% to $58.93 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Invivyd, Inc. (NASDAQ:IVVD) shares surged 170% to $4.40 after the company reported positive initial results from ongoing CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the Prevention of COVID-19. Cuentas Inc. (NASDAQ:CUEN) shares climbed 71.6% to $2.37. iCoreConnect Inc. (NASDAQ:ICCT) shares jumped 49.4% t
Gainers Invivyd (NASDAQ:IVVD) stock moved upwards by 157.7% to $4.2 during Monday's regular session. The market value of their outstanding shares is at $462.4 million. Panbela Therapeutics (NASDAQ:PBLA) stock rose 123.14% to $1.02. The market value of their outstanding shares is at $5.2 million. Biomerica (NASDAQ:BMRA) shares increased by 65.64% to $1.64. The market value of their outstanding shares is at $27.5 million. ZimVie (NASDAQ:ZIMV) shares increased by 42.24% to $15.96. The company's market cap stands at $423.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 37.58% to $0.83. The company's market cap stands at $18.8 million. SenesTech (NASDAQ:SNES) stock moved upw